US Stock MarketDetailed Quotes

AIM AIM ImmunoTech

Watchlist

0.3599
+0.0049+1.38%

Close Aug 29 16:00 ET

0.3700
+0.0101+2.81%

Post 20:02 ET

20.56MMarket Cap-631P/E (TTM)

AIM ImmunoTech Stock Forum

Trytosaveabit

Aug 20 07:32

Update

$AIM ImmunoTech (AIM.US)$ Reuters
2 mins ago
AIM ImmunoTech Announces Print Publication and Further Positive Findings From a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

HotShot369

Jul 24 08:26

bought this all today. let's see how this goes

Share Your Profit/Loss

Trytosaveabit

Jul 24 08:01

Update

$AIM ImmunoTech (AIM.US)$ Aim Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy

Mafiosa818

Jun 6 14:36

$AIM ImmunoTech (AIM.US)$ 👀

MonkeyGee

Jun 6 14:35

Avian Flu Play

$AIM ImmunoTech (AIM.US)$

AIM ImmunoTech(AIM) 0.4648 +23.62%

Trytosaveabit

Apr 29 08:00

Update

$AIM ImmunoTech (AIM.US)$ AIM ImmunoTech Announces First Dose Level Is Generally Well-Tolerated in Phase 1B/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer

Jaguar8

Apr 10 07:26

$AIM ImmunoTech (AIM.US)$
NEWS
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM ImmunoTech Inc. announced promising interim data showing that combining Ampligen with Keytruda in treating recurrent ovarian cancer could have a powerful synergistic effect, significantly increasing response rates and progression-free survival. The study also highlighted increased an...

Trytosaveabit

Mar 25 08:16

Update

$AIM ImmunoTech (AIM.US)$ AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Trytosaveabit

Feb 8 07:52

Update

$AIM ImmunoTech (AIM.US)$ AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions 2 MINUTES AGO, 8:50 AM EST VIA GLOBENEWSWIRE

Trytosaveabit

Jan 24 08:14

Update

$AIM ImmunoTech (AIM.US)$ AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer 3 MINUTES AGO, 9:10 AM EST VIA GLOBENEWSWIRE

No comment yet

Analysis

Analyst Rating

No Data

Price Target

No Data

Overall